Carl Zeiss Meditec AG (CZMWF)
USD 66.58
(15.05%)
USD 66.58
(15.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 878.62 Million EUR | 17.37% |
| 2022 | 730.71 Million EUR | 23.1% |
| 2021 | 593.59 Million EUR | 4.51% |
| 2020 | 567.96 Million EUR | 0.13% |
| 2019 | 567.22 Million EUR | 10.51% |
| 2018 | 513.25 Million EUR | 5.95% |
| 2017 | 484.43 Million EUR | 13.93% |
| 2016 | 425.21 Million EUR | 3.94% |
| 2015 | 409.09 Million EUR | 11.27% |
| 2014 | 367.66 Million EUR | 3.88% |
| 2013 | 353.94 Million EUR | 4.57% |
| 2012 | 338.46 Million EUR | 8.74% |
| 2011 | 311.27 Million EUR | 14.44% |
| 2010 | 271.98 Million EUR | 18.33% |
| 2009 | 229.84 Million EUR | -7.59% |
| 2008 | 248.71 Million EUR | 10.41% |
| 2007 | 225.27 Million EUR | 299.03% |
| 2006 | -113.18 Million EUR | -13.62% |
| 2005 | -99.62 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 839 Million EUR | 301.44% |
| 2024 Q1 | 209 Million EUR | -11.87% |
| 2024 Q3 | 239.07 Million EUR | -71.5% |
| 2023 Q4 | 237.14 Million EUR | 10.37% |
| 2023 Q2 | 208.55 Million EUR | 5.81% |
| 2023 Q1 | 197.1 Million EUR | -10.98% |
| 2023 Q3 | 214.85 Million EUR | 3.02% |
| 2023 FY | 857.64 Million EUR | 17.37% |
| 2022 FY | 730.71 Million EUR | 23.1% |
| 2022 Q1 | 158.4 Million EUR | -10.51% |
| 2022 Q2 | 165.61 Million EUR | 4.56% |
| 2022 Q3 | 185.27 Million EUR | 11.87% |
| 2022 Q4 | 221.41 Million EUR | 19.51% |
| 2021 Q1 | 133.9 Million EUR | -7.31% |
| 2021 Q4 | 176.99 Million EUR | 25.3% |
| 2021 Q3 | 141.26 Million EUR | -0.16% |
| 2021 Q2 | 141.48 Million EUR | 5.66% |
| 2021 FY | 593.59 Million EUR | 4.51% |
| 2020 Q2 | 145.76 Million EUR | -2.5% |
| 2020 FY | 567.96 Million EUR | 0.13% |
| 2020 Q4 | 144.46 Million EUR | 12.63% |
| 2020 Q3 | 128.26 Million EUR | -12.0% |
| 2020 Q1 | 149.5 Million EUR | -10.76% |
| 2019 Q1 | 129.5 Million EUR | -7.54% |
| 2019 Q2 | 133.12 Million EUR | 2.8% |
| 2019 Q3 | 137.08 Million EUR | 2.98% |
| 2019 Q4 | 167.52 Million EUR | 22.2% |
| 2019 FY | 567.22 Million EUR | 10.51% |
| 2018 FY | 513.25 Million EUR | 5.95% |
| 2018 Q1 | 124.1 Million EUR | -10.09% |
| 2018 Q2 | 122.96 Million EUR | -0.91% |
| 2018 Q3 | 126.16 Million EUR | 2.6% |
| 2018 Q4 | 140.05 Million EUR | 11.01% |
| 2017 Q4 | 138.03 Million EUR | 15.73% |
| 2017 Q3 | 119.27 Million EUR | 2.59% |
| 2017 Q2 | 116.26 Million EUR | 4.84% |
| 2017 Q1 | 110.9 Million EUR | -1.83% |
| 2017 FY | 484.43 Million EUR | 13.93% |
| 2016 Q1 | 104.66 Million EUR | -1.97% |
| 2016 Q3 | 102.42 Million EUR | -2.59% |
| 2016 Q4 | 112.97 Million EUR | 10.3% |
| 2016 FY | 425.21 Million EUR | 3.94% |
| 2016 Q2 | 105.14 Million EUR | 0.46% |
| 2015 FY | 409.09 Million EUR | 11.27% |
| 2015 Q4 | 106.77 Million EUR | 4.43% |
| 2015 Q2 | 100.4 Million EUR | 0.74% |
| 2015 Q1 | 99.66 Million EUR | -0.04% |
| 2015 Q3 | 102.24 Million EUR | 1.84% |
| 2014 Q2 | 91.14 Million EUR | 4.2% |
| 2014 FY | 367.66 Million EUR | 3.88% |
| 2014 Q4 | 99.7 Million EUR | 11.58% |
| 2014 Q3 | 89.35 Million EUR | -1.96% |
| 2014 Q1 | 87.47 Million EUR | -9.76% |
| 2013 Q1 | 86.17 Million EUR | -1.45% |
| 2013 FY | 353.94 Million EUR | 4.57% |
| 2013 Q2 | 85.25 Million EUR | -1.07% |
| 2013 Q3 | 85.58 Million EUR | 0.39% |
| 2013 Q4 | 96.93 Million EUR | 13.26% |
| 2012 Q4 | 87.44 Million EUR | 6.14% |
| 2012 Q1 | 81.96 Million EUR | -6.93% |
| 2012 FY | 338.46 Million EUR | 8.74% |
| 2012 Q3 | 82.37 Million EUR | -4.96% |
| 2012 Q2 | 86.67 Million EUR | 5.75% |
| 2011 Q3 | 73.22 Million EUR | -3.39% |
| 2011 Q1 | 74.17 Million EUR | -2.94% |
| 2011 Q2 | 75.79 Million EUR | 2.19% |
| 2011 Q4 | 88.07 Million EUR | 20.28% |
| 2011 FY | 311.27 Million EUR | 14.44% |
| 2010 FY | 271.98 Million EUR | 18.33% |
| 2010 Q2 | 66.21 Million EUR | 9.37% |
| 2010 Q3 | 68.8 Million EUR | 3.92% |
| 2010 Q4 | 76.41 Million EUR | 11.06% |
| 2010 Q1 | 60.54 Million EUR | 43.12% |
| 2009 Q2 | 63.31 Million EUR | -6.97% |
| 2009 Q3 | 56.17 Million EUR | -11.28% |
| 2009 FY | 229.84 Million EUR | -7.59% |
| 2009 Q4 | 42.3 Million EUR | -24.69% |
| 2009 Q1 | 68.05 Million EUR | 0.0% |
| 2008 FY | 248.71 Million EUR | 10.41% |
| 2007 FY | 225.27 Million EUR | 299.03% |
| 2006 FY | -113.18 Million EUR | -13.62% |
| 2005 FY | -99.62 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | -30585.598% |
| Ansell Limited | 495.5 Million USD | -77.322% |
| Ansell Limited | 495.5 Million USD | -77.322% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 82.8 Million USD | -961.098% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 1.73 Million USD | -50665.619% |
| Psykey, Inc. | 1.21 Million USD | -72305.726% |
| ConvaTec Group Plc | 910.31 Million USD | 3.481% |
| ConvaTec Group Plc | 872.5 Million USD | -0.702% |
| Encision Inc. | 3.77 Million USD | -23164.186% |
| Golden Valley Development, Inc | 141.81 Thousand USD | -619477.466% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | -799154.987% |
| Innovative MedTech Inc. | 6.09 Million USD | -14306.113% |
| LifePoint, Inc. | 7.42 Million USD | -11735.188% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | -13738.857% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | -102663.626% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 726.13 Thousand USD | -120900.945% |
| Reflect Scientific, Inc. | 1.06 Million USD | -82501.281% |
| SmileDirectClub, Inc. | 517 Million USD | -69.947% |
| Sector 10, Inc. | 39.84 Thousand USD | -2205072.673% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 86.774% |
| SheerVision, Inc. | 2.33 Million USD | -37582.956% |
| United Health Products, Inc. | 2.42 Million USD | -36109.144% |
| Vasamed, Inc. | 4.67 Million USD | -18702.593% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | -34197.276% |
| Yubo International Biotech Limited | 1.25 Million USD | -69750.263% |